-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 10.3% Higher
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading 10.3% Higher
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating)'s share price was up 10.3% during mid-day trading on Friday . The company traded as high as $12.99 and last traded at $12.89. Approximately 24,159 shares traded hands during trading, a decline of 93% from the average daily volume of 346,162 shares. The stock had previously closed at $11.69.
Kiniksa Pharmaceuticals Stock Up 14.7 %
The company has a market cap of $929.04 million, a PE ratio of -8.28 and a beta of -0.12. The stock's 50 day moving average is $9.96 and its 200-day moving average is $10.03.
Get Kiniksa Pharmaceuticals alerts:Institutional Investors Weigh In On Kiniksa Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Pictet Asset Management SA raised its stake in Kiniksa Pharmaceuticals by 6.4% during the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after purchasing an additional 213,744 shares in the last quarter. BlackRock Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 0.3% in the first quarter. BlackRock Inc. now owns 3,494,325 shares of the company's stock valued at $34,734,000 after acquiring an additional 10,473 shares during the period. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 4.0% in the first quarter. Vanguard Group Inc. now owns 3,006,650 shares of the company's stock valued at $29,886,000 after acquiring an additional 115,942 shares during the period. Great Point Partners LLC raised its stake in shares of Kiniksa Pharmaceuticals by 108.3% in the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock valued at $11,114,000 after acquiring an additional 581,329 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Hedge funds and other institutional investors own 42.57% of the company's stock.
About Kiniksa Pharmaceuticals
(Get Rating)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Read More
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating)'s share price was up 10.3% during mid-day trading on Friday . The company traded as high as $12.99 and last traded at $12.89. Approximately 24,159 shares traded hands during trading, a decline of 93% from the average daily volume of 346,162 shares. The stock had previously closed at $11.69.
納斯達克週五午盤交易中,Kiniksa PharmPharmticals,Ltd.股價上漲10.3%,最高報12.99美元,最新報12.89美元。全天約有24,159股易手,較346,162股的日均成交量下降93%。此前該股收盤價為11.69美元。
Kiniksa Pharmaceuticals Stock Up 14.7 %
Kiniksa製藥類股上漲14.7%
The company has a market cap of $929.04 million, a PE ratio of -8.28 and a beta of -0.12. The stock's 50 day moving average is $9.96 and its 200-day moving average is $10.03.
該公司市值為9.2904億美元,市盈率為-8.28,貝塔係數為-0.12。該股的50日移動均線切入位在9.96美元,200日移動均線切入位在10.03美元。
Institutional Investors Weigh In On Kiniksa Pharmaceuticals
機構投資者看好Kiniksa製藥公司
A number of hedge funds have recently bought and sold shares of the business. Pictet Asset Management SA raised its stake in Kiniksa Pharmaceuticals by 6.4% during the fourth quarter. Pictet Asset Management SA now owns 3,548,649 shares of the company's stock valued at $41,768,000 after purchasing an additional 213,744 shares in the last quarter. BlackRock Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 0.3% in the first quarter. BlackRock Inc. now owns 3,494,325 shares of the company's stock valued at $34,734,000 after acquiring an additional 10,473 shares during the period. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 4.0% in the first quarter. Vanguard Group Inc. now owns 3,006,650 shares of the company's stock valued at $29,886,000 after acquiring an additional 115,942 shares during the period. Great Point Partners LLC raised its stake in shares of Kiniksa Pharmaceuticals by 108.3% in the first quarter. Great Point Partners LLC now owns 1,118,067 shares of the company's stock valued at $11,114,000 after acquiring an additional 581,329 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 61.7% in the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after acquiring an additional 357,387 shares during the period. Hedge funds and other institutional investors own 42.57% of the company's stock.
一些對衝基金最近買賣了該公司的股票。Pictet Asset Management SA在第四季度將其在Kiniksa PharmPharmticals的持股增加了6.4%。Pictet Asset Management SA現在擁有該公司3,548,649股股票,價值41,768,000美元,上個季度又購買了213,744股。貝萊德股份有限公司在第一季度增持了0.3%的基尼克薩製藥股份。貝萊德股份有限公司在此期間增持了10,473股,目前持有該公司3,494,325股股票,價值34,734,000美元。先鋒集團在第一季度增持了4.0%的Kiniksa PharmPharmticals股份。先鋒集團在此期間增持了115,942股,目前持有該公司3,006,650股股票,價值29,886,000美元。Great Point Partners LLC在第一季度將其在Kiniksa製藥公司的股份增加了108.3%。Great Point Partners LLC在此期間增持了581,329股,目前擁有1118,067股該公司股票,價值11,114,000美元。最後,高盛股份有限公司在第一季度增持了61.7%的基尼克薩製藥股份。高盛股份有限公司在此期間增持了357,387股,目前持有該公司936,604股股票,價值9,310,000美元。對衝基金和其他機構投資者持有該公司42.57%的股票。
About Kiniksa Pharmaceuticals
關於Kiniksa製藥公司
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Kiniksa製藥有限公司是一家生物製藥公司,專注於發現、獲得、開發治療藥物,並將其商業化,用於治療世界各地嚴重未得到滿足的醫療需求的衰弱疾病患者。它的候選產品包括用於治療複發性心包炎的ARCALYST,這是一種炎症性心血管疾病,是一種治療複發性心包炎的藥物;Mavrilimumab,一種完成了治療鉅細胞動脈炎的第二階段臨牀試驗的單抗;Vixarelimab,一種處於2a期臨牀試驗的單抗,用於治療慢性炎症性皮膚疾病結節性瘙癢;以及KPL-404,一種CD40-CD154相互作用的單抗抑制物,一種對B細胞成熟、免疫球蛋白類別轉換和1型免疫反應至關重要的T細胞共刺激信號。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於Kiniksa製藥公司(KNSA)的研究報告
- MarketBeat:回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
- Beyond Meat不是沒有希望,而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Kiniksa製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Kiniksa製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧